Crossmark

A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)

Crossref DOI link: https://doi.org/10.1186/s13063-019-3606-y

Published Online: 2019-08-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Ramsey, Mitchell L.

Nuttall, Janet

Hart, Phil A.
Funding

Funding for this research was provided by:

Nichi Iko (Not applicable)
License Information

Text and Data Mining valid from 2019-08-14

Version of Record valid from 2019-08-14
More Information

Article History

Received: 20 November 2018

Accepted: 20 July 2019

First Online: 14 August 2019

Ethics approval and consent to participate

: The study protocol has been reviewed and approved by Copernicus Group, Independent Review Board (IRB), IRB tracking number SYN3–15-614, and was approved by each participating center’s IRB. The IRB approval for the phase I study was granted 9 November 2015 and the IRB approval for the phase II study was granted on 18 January 2016. Written informed consent for study participation and use of collected data and biologic specimens for ancillary studies will be obtained from subjects or authorized surrogates by study site personnel.

: Not applicable.

: MR has no disclosures.JN is employed by Kangen Pharmaceuticals America, LLC.PH has served as a consultant for Abbvie, Inc. and Kangen Pharmaceuticals America, LLC (formerly KC Specialty Therapeutics, LLC).

Document is current

Any future updates will be listed below